Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Non-Hodgkin 6Neoplasm Metastasis 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Multiple Myeloma 2Lymphoma, Follicular 2Endometrial Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Thyroid cancer, follicular 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Spinocerebellar Degenerations 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Renal Insufficiency 1Recurrence 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Malignant Solid Neoplasm 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hepatic Insufficiency 1Gallbladder Neoplasms 1Digestive System Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1

Interventions

rucaparib 1olaparib 1durvalumab 1copanlisib 1cediranib 1capivasertib 1cabozantinib 1adavosertib 1Specimen Handling 1Radiation 1Platinum 1Nivolumab 1Immunoglobulin G 1Fluid Therapy 1Disulfides 1Congresses as Topic 1Cisplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Endometrioid × copanlisib × Clear all
NCT02728258 2022-02-15

Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer

NRG Oncology

Phase 2 Completed
11 enrolled 12 charts

Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡